Question 1

Does Boston Trust Walden own ANIK stock?

Accepted Answer

No. Boston Trust Walden exited its ANIK (Anika Therapeutics) position in Q2 2021. Its Q1 2021 13F listed 375,070 shares worth $15.3M.

Question 2

How many shares of ANIK does Boston Trust Walden own?

Accepted Answer

None since Q2 2021, when Boston Trust Walden exited the position. Its Q1 2021 13F listed 375,070 shares worth $15.3M.

Question 3

What is Boston Trust Walden's ANIK position worth?

Accepted Answer

Boston Trust Walden's ANIK position was worth $15.3M in its Q1 2021 13F, before the exit in Q2 2021.

Question 4

Is Boston Trust Walden buying or selling ANIK?

Accepted Answer

In Q2 2021, Boston Trust Walden exited its entire ANIK position.

Question 5

When did Boston Trust Walden first buy ANIK?

Accepted Answer

Boston Trust Walden already held ANIK in its Q1 2019 13F, the earliest on record, and listed it in 9 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2021-Q2 Latest	Exited	0	-100.0%	$0	0.0%	$43.29	0
2021-Q1	Decreased	375,070	-0.8%	$15.3M	0.1%	$40.79	0
2020-Q4	Increased	378,167	+0.7%	$17.1M	0.2%	$45.26	34
2020-Q3	Increased	375,498	+4.8%	$13.3M	0.2%	$35.39	35
2020-Q2	Increased	358,482	+9.9%	$13.5M	0.2%	$37.73	37
2020-Q1	Increased	326,319	+48.5%	$9.4M	0.2%	$28.91	45
2019-Q4	Decreased	219,818	-40.8%	$11.4M	0.1%	$51.85	0
2019-Q3	Increased	371,596	+0.1%	$20.4M	0.3%	$54.89	34
2019-Q2	Increased	371,190	+40.9%	$15.1M	0.2%	$40.62	45
2019-Q1	First report	263,515	-	$8M	0.1%	$30.24	0